gms | German Medical Science

58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

26. bis 29.04.2007, Leipzig

Lisuride has antiepileptic potential and reduces brain swelling after controlled cortical impact injury in rats

Lisurid wirkt antikonvulsiv und reduziert die posttraumatische Hirnschwellung nach Controlled Cortical Impact Trauma an der Ratte.

Meeting Abstract

  • corresponding author K. Zweckberger - Klinik für Neurochirurgie, Universität Heidelberg
  • O. W. Sakowitz - Klinik für Neurochirurgie, Universität Heidelberg
  • C. Schardt - Klinik für Neurochirurgie, Universität Heidelberg
  • K. L. Kiening - Klinik für Neurochirurgie, Universität Heidelberg
  • A. W. Unterberg - Klinik für Neurochirurgie, Universität Heidelberg

Deutsche Gesellschaft für Neurochirurgie. 58. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC). Leipzig, 26.-29.04.2007. Düsseldorf: German Medical Science GMS Publishing House; 2007. DocP 054

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dgnc2007/07dgnc309.shtml

Veröffentlicht: 11. April 2007

© 2007 Zweckberger et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Objective: In addition to dopaminergic, serotonergic and adrenergic effects Lisuride is a potent antiinflammatory and antioxidative agent. The aim of this study was to examine if Lisuride can influence the appearance of early posttraumatic seizures and the development of secondary brain damage after Controlled Cortical Impact injury (CCII) in rats.

Methods: 70 male Sprague-Dawley rats (350-400g) were anesthetized with isoflurane and N2O and a CCI injury (CCII: 7m/s, contact time 300ms, velocity 1.5mm) was performed. 30 minutes after trauma either Lisuride (s.c. bolus:0.3mg/kg BW) or same amounts of physiological NaCl solution were applied as a subcutaneous bolus. In group A (n=18) anesthesia was maintained over 3 hours and MAP, ICP and EEG were digitally recorded. The EEG was analyzed by a blinded investigator. In group B (n=20) osmotic pumps (Alzet®, 2ML1, 0,5 mg/kg/d) were implanted additionally and contusion volume was assessed via T2 weighted MRI scans 8h, 24h, 72h and 7d after CCII. Functional outcome was judged by a Comprehensive Neuroscore. In group C (n=32) osmotic pumps were implanted subcutaneously and animals were sacrified 24h after CCII and 30 minutes after infusion of 2% Evans Blue (EB 2 ml/kgBW). Brain water content was quantified gravimetrically. Differences were found significant if p<0.05.

Results: After trauma EEG activity was reduced significantly without change in the mean frequency. In each group, 6 animals (67%) showed epileptiform discharges. In the verum treated group the absolute number and duration of seizures was reduced (10 vs. 19 respektively 300±100 vs. 100±75s, p<0.1). These were limited to the first 10 minutes after drug treatment. In group C a trend for a decrease in brain water content and EB extravasation was found but there was no difference in contusion volume and Comprehensive Neuroscores (B). Unexpectedly a significant reduction of MAP and CPP was observed directly after injection of Lisuride (MAP: 85±15 mmHg vs. 68±8 mmHg, 60 min. post CCI, p<0.01).

Conclusions: Although Lisuride caused hypotension in the acute phase after CCII, secondary contusion volumes did not increase. This may be due to its antiepileptic properties and reduced brain swelling. It appears that Lisuride has neuroprotective effects and could be a promising substance in the treatment of traumatic brain injury. However, a different dosage needs to be established to avoid hypotension in future studies.